Monopar Therapeutics
MNPR
83.78
+4.21
+5.29%
Monopar Therapeutics
US · MNPR
#3671 by market cap
Listed 2019
83.78
+4.21
+5.29%
Live - 5344 symbols - heartbeat 255s ago
· 2026-10-08 08:54
Pre-market
84.54
+0.91%
After-hours
83.80
+0.02%
Overnight
83.03
-0.90%
- Market cap
- 562.35M
- P/E (TTM)i
- -38.08
- P/Bi
- 4.30
- EPSi
- -1.85
- Div yieldi
- 0.00%
- 52W posi
- 45%
Reader sentiment
Are you bullish or bearish on MNPR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 109.11% -0.18pp
- Institutions
- 114 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund47.10%
Hedge Fund24.02%
VC/PE Fund20.69%
Private Company8.64%
Public Company8.44%
Individual/Insider7.26%
Government Pension Fund0.14%
Top holders as of 2026-06-30
Janus Henderson Group plc
19.55% · 1.31M sh
RA Capital Management, L.P.
9.94% · 667.21K sh
Tactic Pharma LLC
8.46% · 567.58K sh
AstraZeneca PLC
7.79% · 522.67K sh
BlackRock
5.20% · 348.82K sh
Deerfield Management Company, L.P.
4.82% · 323.75K sh
Saturn V Capital Management LP
4.65% · 311.98K sh
Artal Group S.A.
4.02% · 270.12K sh
Vanguard Capital Management, LLC
3.55% · 237.99K sh
ADAR1 Capital Management, LLC
3.24% · 217.60K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| Chandler Robinson | Chief Executive Officer | 2.50% |
| Michael Brown | Independent Director | 1.58% |
| Andrew Cittadine | Chief Operating Officer | 0.86% |
| Christopher Starr | Independent Executive Chairman of the Board | 0.22% |
| Lavina Talukdar | Director | 0.21% |
| Kim Tsuchimoto | CFO, Secretary, Treasurer & Director | 0.17% |
| Arthur Klausner | Independent Director | 0.13% |
| Raymond Anderson | Independent Director | 0.08% |
| Patrice Rioux | Acting Chief Medical Officer | 0.08% |
| Quan Vu | CFO, Principal accounting officer & Principal financial officer | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Christopher Starr | Independent Executive Chairman of the Board | Derivative Exercise and Sale | -8,400 | $0.01–79.67 |
| 2026-09-29 | Andrew Cittadine | Chief Operating Officer | Derivative Exercise and Sale | -1,944 | $79.67 |
| 2026-09-29 | Andrew Cittadine | Chief Operating Officer | Derivative Exercise and Retained | +2,440 | -- |
| 2026-09-29 | Chandler Robinson | Chief Executive Officer | Derivative Exercise and Sale | -4,344 | $79.67 |
| 2026-09-29 | Chandler Robinson | Chief Executive Officer | Derivative Exercise and Retained | +5,457 | -- |
| 2026-09-29 | Quan Vu | CFO, Principal accounting officer & Principal financial officer | Derivative Exercise and Sale | -180 | $79.67 |
| 2026-09-29 | Quan Vu | CFO, Principal accounting officer & Principal financial officer | Derivative Exercise and Retained | +434 | -- |
| 2026-09-23 | Chandler Robinson | Chief Executive Officer | Derivative Exercise and Sale | -29,056 | $14.00–89.79 |
| 2026-08-25 | Patrice Rioux | Acting Chief Medical Officer | Derivative Exercise and Sale | -1 | $0.01–111.26 |
| 2026-08-25 | Patrice Rioux | Acting Chief Medical Officer | Other Derivative Acquisition | +1,380 | $0.01 |
| 2026-08-25 | Patrice Rioux | Acting Chief Medical Officer | Derivative Exercise and Retained | +1,379 | $0.01 |
| 2026-08-25 | Kim Tsuchimoto | CFO, Secretary, Treasurer & Director | Automatic Disposition | -4,090 | $108.83–113.84 |
| 2026-08-25 | Kim Tsuchimoto | CFO, Secretary, Treasurer & Director | Derivative Exercise and Sale | -4,090 | $14.00–113.84 |
| 2026-08-25 | Kim Tsuchimoto | CFO, Secretary, Treasurer & Director | Other Derivative Acquisition | +4,090 | $14.00–30.00 |
| 2026-08-24 | Raymond Anderson | Independent Director | Derivative Exercise and Sale | -3,142 | $30.00–113.05 |
| 2026-08-24 | Raymond Anderson | Independent Director | Other Derivative Acquisition | +3,142 | $30.00 |
| 2026-07-07 | Arthur Klausner | Independent Director | Intent to Sell (Form 144) | -5,000 | -- |
| 2026-06-29 | Andrew Cittadine | Chief Operating Officer | Derivative Exercise and Sale | -2,309 | $92.59 |
| 2026-06-29 | Andrew Cittadine | Chief Operating Officer | Derivative Exercise and Retained | +2,945 | -- |
| 2026-06-29 | Chandler Robinson | Chief Executive Officer | Derivative Exercise and Sale | -4,084 | $92.59 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:54:52 · For reference only, not investment advice and not tailored to your situation.